| scholarly article | Q13442814 |
| P2093 | author name string | Jerasak Wannaprasert | |
| Kawin Leelawat | |||
| Siriluck Narong | |||
| Sompong Sakchinabut | |||
| P2860 | cites work | Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer | Q80177528 |
| Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients | Q80288717 | ||
| Cholangiocarcinoma | Q80613536 | ||
| Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma | Q80816569 | ||
| Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts | Q80842997 | ||
| Primary sclerosing cholangitis | Q81781641 | ||
| Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer | Q81814282 | ||
| Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma | Q82244022 | ||
| High lifetime risk of cancer in primary sclerosing cholangitis | Q82625908 | ||
| Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer | Q83842589 | ||
| Liver fluke induces cholangiocarcinoma | Q21092372 | ||
| Matrix metalloproteinases: multifunctional contributors to tumor progression | Q28140150 | ||
| Diagnosis of cholangiocarcinoma | Q30493559 | ||
| Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 | ||
| The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis | Q33886812 | ||
| Serum and bile markers for cholangiocarcinoma | Q33979059 | ||
| Cholangiocarcinoma: lessons from Thailand | Q34034208 | ||
| Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. | Q35878888 | ||
| Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. | Q37157579 | ||
| Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis | Q40023897 | ||
| Hilar cholangiocarcinoma: diagnosis and staging | Q42016929 | ||
| Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma | Q44641391 | ||
| Preanalytical conditions and circulating matrix metalloproteinases | Q46399182 | ||
| Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer | Q46825087 | ||
| Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis | Q46964126 | ||
| Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma | Q48110235 | ||
| Mirizzi syndrome with cholecysto-choledocal fistula with a high CA19-9 level mimicking biliary malignancies: a case report | Q50167599 | ||
| [Expression of epidermal growth factor receptor, ErbB2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma]. | Q53627709 | ||
| The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients | Q59843813 | ||
| Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis | Q70474940 | ||
| Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ? | Q79434609 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| P304 | page(s) | 30 | |
| P577 | publication date | 2009-04-30 | |
| P1433 | published in | BMC Gastroenterology | Q15759922 |
| P1476 | title | Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy | |
| P478 | volume | 9 |
| Q35736066 | A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care |
| Q55403680 | A novel nomogram for the prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis complicated by imagiologically diagnosed mass. |
| Q34836574 | A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma |
| Q38173689 | A review of the clinical diagnosis and therapy of cholangiocarcinoma |
| Q34212347 | A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells |
| Q28732696 | A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses |
| Q35010239 | Bilirubin levels predict malignancy in patients with obstructive jaundice |
| Q96817624 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
| Q38272979 | Diagnostic and prognostic serum marker of cholangiocarcinoma (Review) |
| Q64241138 | Electrochemical Activity Assay for Protease Analysis Using Carbon Nanofiber Nanoelectrode Arrays |
| Q35840582 | Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma |
| Q37226551 | Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. |
| Q27002547 | Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies |
| Q34628852 | Markers of bile duct tumors |
| Q36197398 | Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers |
| Q44400070 | Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma |
| Q45071763 | Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma |
| Q34183196 | Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma |
| Q34582601 | Raf kinase inhibitor protein inhibits cholangiocarcinoma cell metastasis by downregulating matrix metalloproteinase 9 and upregulating tissue inhibitor of metalloproteinase 4 expression |
| Q38368743 | Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases |
| Q35481195 | Serum and biliary MMP-9 and TIMP-1 concentrations in the diagnosis of cholangiocarcinoma |
| Q64067034 | Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases |
| Q36683019 | The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
| Q37964960 | The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma |
Search more.